Indication

PD-L1 positive adenocarcinoma of gastroesophageal junction

PD-L1 positive adenocarcinoma of the gastroesophageal junction refers to a malignant glandular neoplasm arising at the anatomic transition zone between the distal esophagus and proximal stomach, characterized by the measurable expression of programmed death-ligand 1. Read more about PD-L1 positive adenocarcinoma of gastroesophageal junction

4 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common PD-L1 positive adenocarcinoma of gastroesophageal junction therapies.

Showing 1–4 of 4 drugs

OPDIVO (nivolumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT ESOPHAGEAL NEOPLASM·+17
BMS PRIMARYCARE

KEYTRUDA (pembrolizumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+36
Merck Sharp & Dohme
Filter & compare in the drug finder →Opens the drug finder with PD-L1 positive adenocarcinoma of gastroesophageal junction preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About PD-L1 positive adenocarcinoma of gastroesophageal junction.

PD-L1 positive adenocarcinoma of the gastroesophageal junction refers to a malignant glandular neoplasm arising at the anatomic transition zone between the distal esophagus and proximal stomach, characterized by the measurable expression of programmed death-ligand 1.

This condition primarily impacts the upper digestive tract and frequently presents in adults with progressive dysphagia, unintentional weight loss, and early satiety.

Pathophysiologically, the tumor cells or surrounding tumor-infiltrating immune cells express PD-L1—typically quantified using immunohistochemical scoring systems like the Combined Positive Score—which binds to PD-1 receptors on T cells to inhibit antitumor immune surveillance and facilitate tumor immune evasion.

Personalize your experience

Follow PD-L1 positive adenocarcinoma of gastroesophageal junction and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it